Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 163 publications.
Fortuny J, Gilsenan AW, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts. Poster presented at the 35th Annual ICPE Conference; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627.
Herring WL, Zhang Y, Pearson I, Tempest M, Freudensprung U, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis (RRMS) in Scotland. Poster presented at the 2018 American Academy of Neurology Annual Meeting; April 22, 2018. Los Angeles, CA. Previously presented at the 7th Joint ECTRIMS-ACTRIMS Meeting.
Cainzos-Achirica M, Varas-Lorenzo C, Pottegard A, Asmar J, Plana E, Rasmussen L, Bizouard G, Forns J, Hellfritzsch M, Zint K, Perez-Gutthann S, Pladevall-Vila M. Evaluation of potential off-label prescribing of dabigatran etexilate in France, Denmark, and the United Kingdom and associated methodological challenges. Poster presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE); August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):566. doi: 10.1002/pds.

Pages